Sintilimab

Legend Capital Led a New Round of Investment of Etana

Tuesday, September 14, 2021 - 12:42am

HONG KONG, Sept 14, 2021 - (ACN Newswire) - Legend Capital led a new round of investment of PT Etana Biotechnologies Indonesia (Etana), along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM).

Key Points: 
  • HONG KONG, Sept 14, 2021 - (ACN Newswire) - Legend Capital led a new round of investment of PT Etana Biotechnologies Indonesia (Etana), along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM).
  • Hong Tan, Managing Director of Legend Capital, said "We appreciate Etana's vision to provide Indonesia with cost-effective biopharmaceuticals.
  • Legend Capital is an independent professional venture capital company under Legend Holdings.
  • Its core business is positioned at the initial stage of venture capital and expansion stage growth investment.

Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor)

Thursday, September 2, 2021 - 1:00am

GFH925, GenFleet's lead KRAS G12C candidate, has recently received Investigational New Drug (IND) approval from National Medical Products Administration (NMPA) in China.

Key Points: 
  • GFH925, GenFleet's lead KRAS G12C candidate, has recently received Investigational New Drug (IND) approval from National Medical Products Administration (NMPA) in China.
  • GenFleet will continue to be responsible for supplying GFH925 for both development and commercial purposes in China.
  • If Innovent exercises the option-in rights, GenFleet will receive up to US$50 million of global development support from Innovent.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

Friday, August 27, 2021 - 1:00am

The Boltbody ISAC platform combines a tumor-targeting antibody, a stable non-cleavable linker, and a proprietary immune stimulant.

Key Points: 
  • The Boltbody ISAC platform combines a tumor-targeting antibody, a stable non-cleavable linker, and a proprietary immune stimulant.
  • Bolt will receive an upfront payment of US$5 million in cash from Innovent at signing and a possible future equity investment of up to US$10 million.
  • Furthermore, both Innovent and Bolt are eligible to receive additional milestones payments and royalties associated with the development and commercialization of products in each other's territories.
  • We look forward to collaborating with Innovent on the development of novel ISAC anti-cancer therapeutic candidates," said Randall Schatzman, Ph.D., CEO of Bolt.

Innovent Announces the Establishment of the Scientific Advisory Board

Monday, August 9, 2021 - 12:52am

SAN FRANCISCOand SUZHOU,China, Aug. 8, 2021 /PRNewswire/ --Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceuticalcompany that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,announces today the establishment of Scientific Advisory Board (SAB).

Key Points: 
  • SAN FRANCISCOand SUZHOU,China, Aug. 8, 2021 /PRNewswire/ --Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceuticalcompany that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases,announces today the establishment of Scientific Advisory Board (SAB).
  • The SAB is to provide scientific advices to our research and clinical pipelines that fulfills the mission and vision of Innovent along with the global reach to benefit patients worldwide.
  • Dr. Carlos Garcia-Echeverria, an accomplished drug discovery scientist and pharma executive, bringing 25+ years experiences from EQRx, Sanofi and Novartis.
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology

Friday, August 6, 2021 - 1:00am

In addition, biomarker results from the trial provide important insights for patients with high major histocompatibility complex (MHC) class-II expression.

Key Points: 
  • In addition, biomarker results from the trial provide important insights for patients with high major histocompatibility complex (MHC) class-II expression.
  • These interim data were simultaneously published online by the Journal of Thoracic Oncology.
  • The Journal of Thoracic Oncology manuscript discloses, as of January 15, 2021, with a median follow-up of 22.9 months, the median overall survival (OS) of patients receiving the sintilimab combination was not yet reached.
  • These data showed that this sintilimab combination should be further evaluated as front-line therapy for patients with previously untreated, locally advanced or metastatic nonsquamous non-small cell lung cancer without EGFR or ALK genomic tumor aberrations."

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

Monday, June 7, 2021 - 1:00am

The phase 1 study of IBI110is a dose-escalation trial evaluating IBI110, an anti-LAG-3 monoclonal antibody, as a single agent and in combination with sintilimab in patients with advanced solid tumors refractory to standard of care therapy.

Key Points: 
  • The phase 1 study of IBI110is a dose-escalation trial evaluating IBI110, an anti-LAG-3 monoclonal antibody, as a single agent and in combination with sintilimab in patients with advanced solid tumors refractory to standard of care therapy.
  • The study is comprised of Phase Ia, an IBI110 single-drug dose-escalation phase, and Phase Ib, the dose-escalation phase of IBI110 in combination with sintilimab (200mg).
  • At disease progression, cross over from IBI110 monotherapy to combo (IBI110+ sintlilimab) was allowed at the investigators' discretion.
  • No adverse event (AE) led to discontinuation of IBI110 or sintilimab and no treatment-related death was reported.

Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period

Wednesday, October 7, 2020 - 1:00am

This milestone triggers the $200 million upfront payment milestone referenced in the parties' August 18, 2020 press release.

Key Points: 
  • This milestone triggers the $200 million upfront payment milestone referenced in the parties' August 18, 2020 press release.
  • TYVYT (sintilimab injection) is the only PD-1 inhibitor that has been included in the new Catalogue of the National Reimbursement Drug List (NRDL), in November 2019.
  • In May 2020, TYVYT (sintilimab injection) monotherapy met the primary endpoint in the ORIENT-2 study as second-line therapy in patients with advanced or metastatic esophageal squamous cell carcinoma.
  • In August 2019, Innovent further entered a licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China.

Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement

Tuesday, August 18, 2020 - 11:30am

"We are thrilled to expand on our successful China TYVYT collaboration with Lilly to now include markets outside of China.

Key Points: 
  • "We are thrilled to expand on our successful China TYVYT collaboration with Lilly to now include markets outside of China.
  • TYVYT (sintilimab injection) is an innovative drug with global quality standards jointly developed by Innovent and Lilly in China.
  • Under the agreement, Innovent and Lilly are co-developing and commercializing oncology medicines, including TYVYT (sintilimab injection) in China.
  • In August 2019, Innovent entered into an additional licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China.

Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement

Tuesday, August 18, 2020 - 11:30am

TYVYT (sintilimab injection) is an innovative drug with global quality standards jointly developed by Innovent and Lilly in China.

Key Points: 
  • TYVYT (sintilimab injection) is an innovative drug with global quality standards jointly developed by Innovent and Lilly in China.
  • Under the agreement, Innovent and Lilly are co-developing and commercializing oncology medicines, including TYVYT (sintilimab injection) in China.
  • In August 2019, Innovent entered into an additional licensing agreement with Lilly to develop and commercialize a potentially global best-in-class diabetes medicine in China.
  • In August 2020, Innovent and Lilly announced an expansion of their strategic alliance for TYVYT.

Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)

Monday, June 1, 2020 - 12:30am

ORIENT-4 is a multicenter, single-arm, Phase 2 clinical study evaluating the efficacy and safety of sintilimab in relapsed or refractory extranodal NK/T-cell lymphoma (nasal type).

Key Points: 
  • ORIENT-4 is a multicenter, single-arm, Phase 2 clinical study evaluating the efficacy and safety of sintilimab in relapsed or refractory extranodal NK/T-cell lymphoma (nasal type).
  • A total of 28 subjects were enrolled in the study, all of whom received sintilimab injection (200 mg, IV, Q3W).
  • As of January 17, 2020, the ORR was 67.9% and the complete response (CR) rate was 14.3%.
  • Sintilimab was statistically demonstrated the significant clinical efficacy in the treatment of relapsed or refractory extranodal NK/T-cell lymphoma (nasal type), and could bring long-term benefits to patients."